Background Monoclonal antibodies (mAbs) targeting the epidermal growth factor receptor
(EGFR) prolong survival in metastatic colorectal cancer (mCRC) Kirsten rat sarcoma viral …

EGFR regulates cancer-cell proliferation, apoptosis and tumor-induced neoangiogenesis,
and has been validated as a relevant therapeutic target in several human cancers, including …

The emergence of targeted therapies for the treatment of metastatic colorectal cancer
(mCRC) has considerably improved survival, but has also resulted in a dilemma of …

Metastatic colorectal cancer is a particularly frequent and severe cancer. Patients die mainly
from metastatic disease; however, the survival of these patients has dramatically improved …

Background In the setting of metastatic colorectal cancer (CRC), anti-EGFR antibodies are
not currently recommended for individuals with KRAS mutant tumours. This is based on …

2 Background: Efficacy analyses of the randomized phase III CRYSTAL trial have shown a
significant improvement in progression-free survival (PFS), overall response, and curative …

Abstract Learning Objectives After completing this course, the reader will be able to:
Describe the evolution of cancer chemotherapy for patients with colorectal cancer. Discuss …

RAS family proteins (including KRAS and NRAS) play important roles in the epidermal
growth factor receptor (EGFR) signaling pathway. Mutations in RAS genes (occurring at loci …

Substantial improvements have been made in the management of metastatic colorectal
cancer over the last two decades. The overall survival of patients diagnosed with …

Background The KRAS mutation is not responsible for all cases of resistance to anti–
epidermal growth factor receptors (EGFRs) in metastatic colorectal cancer (mCRC), and new …